Over the past decade or so, the means of producing diagnostic images have improved greatly, but the technology for reading them has failed to keep pace. Radiologists read new computerized images with hand-held magnifying glasses, calipers and rulers, the same tools used for years. R2 Technology, by providing radiologists with better means of reading images through computer-aided detection software, is looking to carve out a niche in the diagnostic imaging market, where few small companies have ventured successfully. R2 is the first-to-market with FDA-approved CAD technology for breast cancer screening, and plans to develop this as a platform technology for other cancers, betting that its first-mover advantage helps establish the industry standard.
by Stephen Levin
Dan Kopans, MD, a prominent radiologist at the Massachusetts General Hospital , starts his mammography seminars by asking how...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
